257 related articles for article (PubMed ID: 16386556)
1. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
Gutiérrez-Dalmau A; Sánchez-Fructuoso A; Sanz-Guajardo A; Mazuecos A; Franco A; Rial MC; Iranzo P; Torregrosa JV; Oppenheimer F; Campistol JM
Transplant Proc; 2005 Nov; 37(9):3836-8. PubMed ID: 16386556
[TBL] [Abstract][Full Text] [Related]
2. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
4. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment.
Zmonarski SC; Boratyńska M; Rabczyński J; Kazimierczak K; Klinger M
Transplant Proc; 2005 Mar; 37(2):964-6. PubMed ID: 15848592
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
6. Conversion to sirolimus in posttransplant renal neoplasms.
Lopez V; Gutierrez C; Cabello M; Burgos D; Sola E; Gonzalez-Molina M
Transplant Proc; 2007 Sep; 39(7):2264-6. PubMed ID: 17889158
[TBL] [Abstract][Full Text] [Related]
7. Conversion to sirolimus in renal transplant recipients: a single-center experience.
Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
[TBL] [Abstract][Full Text] [Related]
8. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
Cardinal H; Froidure A; Dandavino R; Daloze P; Hébert MJ; Colette S; Boucher A
Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
[TBL] [Abstract][Full Text] [Related]
9. Regression of post-transplant Kaposi's sarcoma using sirolimus.
Kolhe N; Mamode N; Van der Walt J; Pattison J
Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
[TBL] [Abstract][Full Text] [Related]
10. Conversion to sirolimus in pediatric renal transplantation recipients.
Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
12. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.
Mohsin N; Budruddin M; Pakkyara A; Darweesh A; Nayyer M; Amitabh J; Daar AS
Exp Clin Transplant; 2005 Dec; 3(2):366-9. PubMed ID: 16417445
[TBL] [Abstract][Full Text] [Related]
13. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
14. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
16. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases.
Yaich S; Charfeddine K; Zaghdane S; El Aoud N; Jarraya F; Kharrat M; Hachicha J
Transplant Proc; 2012 Nov; 44(9):2824-6. PubMed ID: 23146533
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of conversion to sirolimus in 85 renal transplant recipients.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Gonzalez Molina M; Hernandez D
Transplant Proc; 2009; 41(6):2137-8. PubMed ID: 19715855
[TBL] [Abstract][Full Text] [Related]
20. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.
Benavides CA; Pollard VB; Mauiyyedi S; Podder H; Knight R; Kahan BD
Transplantation; 2007 Jul; 84(1):83-8. PubMed ID: 17627242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]